.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Accenture
US Department of Justice
Harvard Business School
UBS
Cantor Fitzgerald
Express Scripts
Colorcon
Dow
Chinese Patent Office

Generated: September 21, 2017

DrugPatentWatch Database Preview

DEXAMETHASONE - Generic Drug Details

« Back to Dashboard

What are the generic sources for dexamethasone and what is the scope of dexamethasone patent protection?

Dexamethasone
is the generic ingredient in thirty-one branded drugs marketed by ECR, Phoenix Labs Ny, West-ward Pharms Int, Sun Pharm Inds, Roxane, Allergan, Watson Labs, Pvt Form, Novartis Pharms Corp, Whiteworth Town Plsn, Merck, Upsher Smith, Xspire Pharma, Par Pharm, Sti Pharma Llc, Wockhardt Eu Operatn, Larken Labs Inc, Organon Usa Inc, Impax Labs, Vintage Pharms, Solvay, Lyne, Allergan Herbert, Alpharma Us Pharms, Idt Australia Ltd, Watson Labs Teva, Mylan Labs Ltd, Ucb Inc, Fresenius Kabi Usa, Intl Medication, Teva Parenteral, Pharmafair, Luitpold, Wyeth Ayerst, Cent Pharms, Alcon, Abraxis Pharm, Bel Mar, Akorn, Dell Labs, Lyphomed, Bausch And Lomb, Sola Barnes Hind, Sandoz Inc, Aurobindo Pharma Ltd, Alcon Pharms Ltd, Perrigo Co Tennessee, and Novartis, and is included in one hundred and twenty-four NDAs. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dexamethasone has one hundred and twenty-five patent family members in twenty-six countries.

There are thirty-nine drug master file entries for dexamethasone. Thirty-six suppliers are listed for this compound.

Summary for Generic Name: DEXAMETHASONE

Tradenames:31
Patents:17
Applicants:48
NDAs:124
Drug Master File Entries: see list39
Suppliers / Packagers: see list36
Bulk Api Vendors: see list76
Clinical Trials: see list1,990
Therapeutic Class:Ophthalmic Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:DEXAMETHASONE at DailyMed

Pharmacology for Ingredient: DEXAMETHASONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Parenteral
DEXAMETHASONE SODIUM PHOSPHATE
dexamethasone sodium phosphate
INJECTABLE;INJECTION081126-001Aug 31, 1990DISCNNoNo► Subscribe► Subscribe► Subscribe
Organon Usa Inc
HEXADROL
dexamethasone
TABLET;ORAL012675-010Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
DEXAMETHASONE SODIUM PHOSPHATE
dexamethasone sodium phosphate
INJECTABLE;INJECTION206781-001Dec 1, 2015APRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Labs Ltd
DEXAMETHASONE SODIUM PHOSPHATE
dexamethasone sodium phosphate
INJECTABLE;INJECTION040803-001Aug 29, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
Organon Usa Inc
HEXADROL
dexamethasone
TABLET;ORAL012675-009Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Allergan
OZURDEX
dexamethasone
IMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Xspire Pharma
DEXAMETHASONE
dexamethasone
TABLET;ORAL088237-001Apr 28, 1983BPRXNoNo► Subscribe► Subscribe► Subscribe
Watson Labs
DEXAMETHASONE
dexamethasone
SUSPENSION/DROPS;OPHTHALMIC089170-001May 9, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
DEXAMETHASONE SODIUM PHOSPHATE
dexamethasone sodium phosphate
SOLUTION/DROPS;OPHTHALMIC, OTIC088771-001Jan 16, 1985ATRXNoYes► Subscribe► Subscribe► Subscribe
Solvay
DEXONE 0.75
dexamethasone
TABLET;ORAL084993-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: dexamethasone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,090,681Methods and apparatus for delivery of ocular implants► Subscribe
7,753,916Methods and apparatus for delivery of ocular implants► Subscribe
7,147,644Apparatus for delivery of ocular implants► Subscribe
8,048,445Ocular implant made by a double extrusion process► Subscribe
7,625,582Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
6,699,493 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
7,468,065Apparatus for delivery of ocular implants► Subscribe
8,778,381Ocular implant made by a double extrusion process► Subscribe
8,828,446Method for reducing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
8,318,070Ocular implant made by a double extrusion process► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: dexamethasone

Country Document Number Estimated Expiration
Canada2429998► Subscribe
BrazilPI0513849► Subscribe
Brazil0115772► Subscribe
Spain2400852► Subscribe
Austria306951► Subscribe
Australia2014201844► Subscribe
Japan2004514702► Subscribe
World Intellectual Property Organization (WIPO)2004062649► Subscribe
New Zealand538380► Subscribe
Australia2010235967► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DEXAMETHASONE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
00552Netherlands► SubscribePRODUCT NAME: VOOR GEBRUIK IN EEN WERKWIJZE VOOR DE BEHANDELING VAN MACULAIR OEDEEM; REG. NO/DATE: EU/1/10/638/001 20100727
2012000081Germany► SubscribePRODUCT NAME: DEXAMETHASON; REGISTRATION NO/DATE: EU/1/10/638/001 20100727
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Healthtrust
Daiichi Sankyo
Queensland Health
Mallinckrodt
Argus Health
Chubb
Medtronic
Express Scripts
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot